English Xeligekimab Cited by user Buidhe on 04 Nov 2023 Xeligekimab (GR1501) is a monoclonal antibody that neutralizes interleukin-17A; it is being developed for plaque psoriasis, axial spondyloarthritis, and lupus nephritis.